-
公开(公告)号：EP2923208B1
公开(公告)日：2019-01-16
申请号：EP13792933.7
申请日：2013-11-21
申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) , Centre National de la Recherche Scientifique (C.N.R.S.) , Assistance Publique Hôpitaux De Paris , Université Paris Descartes , Imagine Institut des Maladies Génétiques Necker Enfants Malades
IPC分类号： G01N33/68 , G01N33/50 , G01N33/569
-
公开(公告)号：EP3331517A1
公开(公告)日：2018-06-13
申请号：EP16750804.3
申请日：2016-08-08
申请人： Centre Hospitalier National d'Ophtalmologie Quinze-Vingts , Institut National de la Santé et de la Recherche Médicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Imagine Institut des Maladies Génétiques Necker Enfants Malades , Assistance Publique - Hôpitaux de Paris , Université Paris Descartes
摘要： The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.
-
3.发明公开
公开(公告)号：EP2923208A1
公开(公告)日：2015-09-30
申请号：EP13792933.7
申请日：2013-11-21
申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Assistance Publique Hôpitaux De Paris , Université Paris Descartes , Imagine Institut des Maladies Génétiques Necker Enfants Malades
IPC分类号： G01N33/68 , G01N33/50 , G01N33/569
CPC分类号： G01N33/505 , G01N33/56972 , G01N33/6893 , G01N2333/55 , G01N2333/7051 , G01N2333/70514 , G01N2800/245 , G01N2800/50 , G01N2800/52
摘要： The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(−) iNKT cell sub-population. In particular, CD3+CD4− TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.
-
公开(公告)号：EP3331517B1
公开(公告)日：2019-11-06
申请号：EP16750804.3
申请日：2016-08-08
申请人： Centre Hospitalier National d'Ophtalmologie Quinze-Vingts , Institut National de la Santé et de la Recherche Médicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Imagine Institut des Maladies Génétiques Necker Enfants Malades , Assistance Publique - Hôpitaux de Paris , Université Paris Descartes
-
5.发明公开
公开(公告)号：EP3154536A1
公开(公告)日：2017-04-19
申请号：EP15731531.8
申请日：2015-06-09
申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) , Fondation Imagine , Assistance Publique-Hôpitaux de Paris (APHP) , Université Paris Descartes , Centre National de la Recherche Scientifique (C.N.R.S.)
发明人： HERMINE, Olivier , ARLET, Jean-Benoit , GUILLEM, Flavia , COURTOIS, Genevève , FONTENAY, Michaela
IPC分类号： A61K31/165 , A61P35/02
CPC分类号： A61K31/422 , A61K31/00 , A61K31/366
摘要： The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
摘要翻译： 本发明提供了设计用于干预该缺陷过程并促进或恢复患有骨髓增生异常综合征的个体的红细胞成熟的方法和药物组合物。 该方法涉及通过防止细胞质中Hsp70的螯合来维持GATA-1的活性。 因此，本发明的目的是通过预防GATA-1的蛋白水解失活来提供恢复或增加患有骨髓增生异常综合征的受试者的红细胞成熟的方法。 在一些实施方案中，通过向受试者施用抑制XPO1核转运蛋白的化合物来实现预防。
-
公开(公告)号：EP3624798A1
公开(公告)日：2020-03-25
申请号：EP18724562.6
申请日：2018-05-17
申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) , Fondation Imagine , Université Paris Descartes , Assistance Publique-Hôpitaux de Paris (APHP) , Centre National de la Recherche Scientifique - CNRS
IPC分类号： A61K31/4402 , A61K31/506 , A61K31/553 , A61P37/00 , A61K45/06
-
7.发明公开
公开(公告)号：EP2880059A1
公开(公告)日：2015-06-10
申请号：EP13748004.2
申请日：2013-08-02
申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Université Paris Descartes , Fondation Imagine , Assistance Publique Hôpitaux De Paris , Université Paris Diderot - Paris 7 , Université Paris-Sud XI
CPC分类号： C07K16/2881 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present disclosure relates to antagonists of transferrin receptor and compositions and methods of use of said antagonists for treating pathological disorders such as thalassemia disorders
-
8.发明公开
公开(公告)号：EP3886983A1
公开(公告)日：2021-10-06
申请号：EP19809483.1
申请日：2019-11-28
申请人： Institut Gustave Roussy , ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS , Imagine Institut des Maladies Génétiques Necker Enfants Malades , Université de Paris , Centre national de la recherche scientifique , Institut National de la Santé et de la Recherche Médicale
IPC分类号： A61P7/06 , A61K31/138 , A61K38/20 , A61K38/18 , A61K38/19 , A61K45/06 , A61K31/135 , A61K31/15 , A61K31/343 , A61K31/4525
-
9.发明公开
公开(公告)号：EP3659672A1
公开(公告)日：2020-06-03
申请号：EP18306579.6
申请日：2018-11-28
申请人： Institut Gustave Roussy , ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS , Imagine Institut des Maladies Génétiques Necker Enfants Malades , Institut National de la Santé et de la Recherche Médicale , UNIVERSITE PARIS DESCARTES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
IPC分类号： A61P7/06 , A61K31/138 , A61K38/20 , A61K38/18 , A61K38/19 , A61K45/06 , A61K31/135 , A61K31/15 , A61K31/343 , A61K31/4525
摘要： The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of aplasia after chemotherapy.
-
10.发明公开
公开(公告)号：EP3256148A1
公开(公告)日：2017-12-20
申请号：EP16704599.6
申请日：2016-02-11
申请人： INSERM - Institut National de la Santé et de la Recherche Médicale , Université Paris Descartes , Centre National de la Recherche Scientifique (C.N.R.S.) , Fondation Imagine , Assistance Publique-Hôpitaux de Paris (APHP) , Universite de Nantes , Université d'Angers , Centre Hospitalier Universitaire d'Angers
发明人： CRUZ-MOURA, Ivan , BARDET, Valérie , DUSSIOT, Michaël , TROVATI MACIEL, Thiago , TAMBURINI, Jérôme , IFRAH, Norbert , HERMINE, Olivier
IPC分类号： A61K38/18 , C12Q1/68 , G01N33/574
CPC分类号： G01N33/74 , A61K39/3955 , C07K16/22 , C07K2317/76 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57426 , G01N2333/475 , G01N2333/51 , G01N2800/22 , G01N2800/52
摘要： The present invention relates to antagonists of GDF11, for use in the treatment of malignant hematological disease, such as Acute Myeloid Leukemia (AML). The present invention also relates to a method for predicting the responsiveness of a patient affected with malignant haematological disease, such as Acute Myeloid Leukemia, to a chemotherapy treatment.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.026 秒)
